Integral Health Asset Management LLC Decreases Stake in Oric Pharmaceuticals, Inc. $ORIC

Integral Health Asset Management LLC cut its stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 28.0% during the third quarter, HoldingsChannel.com reports. The firm owned 900,000 shares of the company’s stock after selling 350,000 shares during the period. Integral Health Asset Management LLC’s holdings in Oric Pharmaceuticals were worth $10,800,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Assetmark Inc. acquired a new stake in shares of Oric Pharmaceuticals in the third quarter valued at about $37,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Oric Pharmaceuticals by 36.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,755 shares of the company’s stock valued at $45,000 after purchasing an additional 1,009 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Oric Pharmaceuticals in the 3rd quarter valued at approximately $60,000. KLP Kapitalforvaltning AS acquired a new position in Oric Pharmaceuticals during the third quarter worth $85,000. Finally, Creative Planning purchased a new stake in Oric Pharmaceuticals during the second quarter worth $113,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Price Performance

Shares of NASDAQ ORIC opened at $11.90 on Friday. The company has a 50-day simple moving average of $11.32 and a 200-day simple moving average of $11.23. The company has a market cap of $1.19 billion, a PE ratio of -7.83 and a beta of 1.28. Oric Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.04. On average, analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Dominic Piscitelli sold 52,000 shares of the stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares in the company, valued at approximately $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jacob Chacko sold 33,374 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total value of $302,368.44. Following the sale, the chief executive officer owned 581,711 shares in the company, valued at approximately $5,270,301.66. The trade was a 5.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 106,814 shares of company stock valued at $1,199,135 over the last quarter. Company insiders own 6.82% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on ORIC shares. Wolfe Research began coverage on Oric Pharmaceuticals in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Oric Pharmaceuticals in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Wells Fargo & Company raised their target price on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Finally, Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.20.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.